Prophylactic human papillomavirus vaccination: a breakthrough in primary cervical cancer prevention.
Nearly all cervical cancers require human papillomavirus infection (HPV) for subsequent carcinogenesis. The identification of this obligate viral etiology, in addition to a vast knowledge about the HPV viral life cycle and resultant host response, has led to a vaccine approach to cervical cancer prevention. The use of prophylactic cancer vaccine as primary prevention holds the most promise for long-term cancer prevention but raises some important and as yet unanswered questions that are addressed in this article.
Obstetrics and Gynecology, Public Health and Mexican-American Studies, National Center of Excellence in Women's Health, The University of Arizona, University Medical Center, 1501 North Campbell Avenue, Tucson, AZ 85724, USA. fcisco@u.arizona.edu
Francisco A R
FA
Garcia
Debbie
D
Saslow
D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D030361:Papillomavirus Infections / Q000150:complications / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D011322:Primary Prevention; D012449:Safety; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control* / Q000821:virology
D053918:Papillomavirus Vaccines